Loxo Oncology Inc. (LOXO) and ImmuCell Corporation (NASDAQ:ICCC) Comparison side by side

This is therefore a contrasting of the institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation in Loxo Oncology Inc. (NASDAQ:LOXO) and ImmuCell Corporation (NASDAQ:ICCC). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Loxo Oncology Inc. 144.80M 49.86 62.98M -2.08 0.00
ImmuCell Corporation 11.18M 3.88 1.46M -0.28 0.00

Demonstrates Loxo Oncology Inc. and ImmuCell Corporation earnings per share (EPS), top-line revenue and valuation.


Table 2 provides us the return on equity, net margins and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
Loxo Oncology Inc. -43.49% -16.4% -8.7%
ImmuCell Corporation -13.06% -6.3% -4.4%

Risk and Volatility

Loxo Oncology Inc. has a 2.22 beta, while its volatility is 122.00%, thus making it more volatile than Standard & Poor’s 500. ImmuCell Corporation’s 1.38 beta is the reason why it is 38.00% more volatile than Standard & Poor’s 500.


Loxo Oncology Inc.’s Current Ratio and Quick Ratio are 3.6 and 3.6 respectively. The Current Ratio and Quick Ratio of its competitor ImmuCell Corporation are 3.2 and 2.1 respectively. Loxo Oncology Inc. therefore has a better chance of paying off short and long-term obligations compared to ImmuCell Corporation.

Analyst Recommendations

The next table highlights the delivered recommendations and ratings for Loxo Oncology Inc. and ImmuCell Corporation.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Loxo Oncology Inc. 0 1 5 2.83
ImmuCell Corporation 0 0 0 0.00

Loxo Oncology Inc.’s downside potential currently stands at -11.53% and an $207.67 average target price.

Insider & Institutional Ownership

Loxo Oncology Inc. and ImmuCell Corporation has shares owned by institutional investors as follows: 99.2% and 14.2%. About 7.3% of Loxo Oncology Inc.’s share are owned by insiders. Competitively, 4.2% are ImmuCell Corporation’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Loxo Oncology Inc. -3.59% -23.23% -18.07% -24.66% 70.01% 60.82%
ImmuCell Corporation -0.53% -6.54% 9.22% 5.67% -16.09% -15.13%

For the past year Loxo Oncology Inc. had bullish trend while ImmuCell Corporation had bearish trend.


On 6 of the 11 factors ImmuCell Corporation beats Loxo Oncology Inc.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

ImmuCell Corporation develops, acquires, manufactures, and sells products that enhance animal health and productivity of cows for the dairy and beef industries in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; Wipe Out Dairy Wipes, which consist of towelettes that are pre-moistened with a Nisin-based formulation to prepare the teat area of a cow in advance of milking; and California Mastitis Test that could be used for bulk tank and individual cow sample monitoring, as well as to determine which quarter of the udder is mastitic. It is also involved in the development of Mast Out, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and treatments that prevent E. coli K99 and bovine coronavirus, as well as calf scours caused by enteric pathogens. In addition, the company sells various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to distributors and bovine veterinarians, as well as directly to producers. The company was founded in 1982 and is based in Portland, Maine.